BUSINESS
Expert Expects New 21-Valent Pneumococcal Shot Capvaxive to Curb Invasive Disease
A new 21-valent pneumococcal conjugate vaccine, Capvaxive, could help prevent severe pneumococcal infections by covering serotypes associated with high fatality and drug resistance, according to pulmonologist Hiroshi Mukae of Nagasaki University. Speaking at an MSD-hosted seminar on November 21, Mukae…
To read the full story
Related Article
- MSD Launches 21-Valent Pneumococcal Vaccine Capvaxive in Japan
October 30, 2025
BUSINESS
- Lunsumio Combo Hits PIII Goal in Follicular Lymphoma: Roche
September 18, 2026
- Padcev-Keytruda Gets CHMP Nod for Expanded MIBC Use
September 18, 2026
- SanBio Eyes October Start for Akuugo Treatment
September 18, 2026
- Toho Unit to Launch Pharma-Wholesaler Payment Service
September 18, 2026
- Astellas Names Marino General Counsel, Compliance Chief
September 18, 2026
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…





